155 related articles for article (PubMed ID: 27378523)
1. Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity.
Chen Z; Wang Z; Pang JC; Yu Y; Bieerkehazhi S; Lu J; Hu T; Zhao Y; Xu X; Zhang H; Yi JS; Liu S; Yang J
Sci Rep; 2016 Jul; 6():29090. PubMed ID: 27378523
[TBL] [Abstract][Full Text] [Related]
2. Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.
Dolman ME; Poon E; Ebus ME; den Hartog IJ; van Noesel CJ; Jamin Y; Hallsworth A; Robinson SP; Petrie K; Sparidans RW; Kok RJ; Versteeg R; Caron HN; Chesler L; Molenaar JJ
Clin Cancer Res; 2015 Nov; 21(22):5100-9. PubMed ID: 26202950
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of dinaciclib and CAN508 hybrids as CDK inhibitors.
Odeh DM; Allam HA; Baselious F; Mahmoud WR; Odeh MM; Ibrahim HS; Abdel-Aziz HA; Mohammed ER
Drug Dev Res; 2024 May; 85(3):e22193. PubMed ID: 38685605
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor.
Whittaker SR; Barlow C; Martin MP; Mancusi C; Wagner S; Self A; Barrie E; Te Poele R; Sharp S; Brown N; Wilson S; Jackson W; Fischer PM; Clarke PA; Walton MI; McDonald E; Blagg J; Noble M; Garrett MD; Workman P
Mol Oncol; 2018 Mar; 12(3):287-304. PubMed ID: 29063678
[TBL] [Abstract][Full Text] [Related]
5. Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma.
Poon E; Liang T; Jamin Y; Walz S; Kwok C; Hakkert A; Barker K; Urban Z; Thway K; Zeid R; Hallsworth A; Box G; Ebus ME; Licciardello MP; Sbirkov Y; Lazaro G; Calton E; Costa BM; Valenti M; De Haven Brandon A; Webber H; Tardif N; Almeida GS; Christova R; Boysen G; Richards MW; Barone G; Ford A; Bayliss R; Clarke PA; De Bono J; Gray NS; Blagg J; Robinson SP; Eccles SA; Zheleva D; Bradner JE; Molenaar J; Vivanco I; Eilers M; Workman P; Lin CY; Chesler L
J Clin Invest; 2020 Nov; 130(11):5875-5892. PubMed ID: 33016930
[TBL] [Abstract][Full Text] [Related]
6. Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes.
Lebedev T; Vagapova E; Spirin P; Rubtsov P; Astashkova O; Mikheeva A; Sorokin M; Vladimirova U; Suntsova M; Konovalov D; Roumiantsev A; Stocking C; Buzdin A; Prassolov V
Oncogene; 2021 Nov; 40(44):6258-6272. PubMed ID: 34556815
[TBL] [Abstract][Full Text] [Related]
7. Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.
Azimi A; Caramuta S; Seashore-Ludlow B; Boström J; Robinson JL; Edfors F; Tuominen R; Kemper K; Krijgsman O; Peeper DS; Nielsen J; Hansson J; Egyhazi Brage S; Altun M; Uhlen M; Maddalo G
Mol Syst Biol; 2018 Mar; 14(3):e7858. PubMed ID: 29507054
[TBL] [Abstract][Full Text] [Related]
8. Dinaciclib potently suppresses MCL-1 and selectively induces the cell death in human iPS cells without affecting the viability of cardiac tissue.
Alsayegh K; Matsuura K; Sekine H; Shimizu T
Sci Rep; 2017 Mar; 7():45577. PubMed ID: 28361959
[TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth
Chen Z; Zhao Y; Yu Y; Pang JC; Woodfield SE; Tao L; Guan S; Zhang H; Bieerkehazhi S; Shi Y; Patel R; Vasudevan SA; Yi JS; Muscal JA; Xu GT; Yang J
Oncotarget; 2017 Nov; 8(61):104090-104103. PubMed ID: 29262623
[TBL] [Abstract][Full Text] [Related]
10. The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study.
Rossini E; Tamburello M; Abate A; Zini S; Ribaudo G; Gianoncelli A; Calza S; Valcamonico F; Suardi NR; Mirabella G; Berruti A; Sigala S
Cells; 2024 Feb; 13(5):. PubMed ID: 38474332
[TBL] [Abstract][Full Text] [Related]
11. Identification of a Novel Selective CDK9 Inhibitor for the Treatment of CRC: Design, Synthesis, and Biological Activity Evaluation.
Zhong Y; Xu J; Zhou R; Tang L; Ding S; Ren Z; Song N; Hu B; Yang H; Sun Y; Cheng M; Li J; Liu Y
J Med Chem; 2024 Mar; 67(6):4739-4756. PubMed ID: 38488882
[TBL] [Abstract][Full Text] [Related]
12. Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers.
Freeman DB; Hopkins TD; Mikochik PJ; Vacca JP; Gao H; Naylor-Olsen A; Rudra S; Li H; Pop MS; Villagomez RA; Lee C; Li H; Zhou M; Saffran DC; Rioux N; Hood TR; Day MAL; McKeown MR; Lin CY; Bischofberger N; Trotter BW
J Med Chem; 2023 Dec; 66(23):15629-15647. PubMed ID: 37967851
[TBL] [Abstract][Full Text] [Related]
13. MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer.
Zhang H; Huang C; Gordon J; Yu S; Morton G; Childers W; Abou-Gharbia M; Zhang Y; Jelinek J; Issa JJ
Clin Epigenetics; 2024 Jan; 16(1):3. PubMed ID: 38172923
[TBL] [Abstract][Full Text] [Related]
14. A preclinical platform for assessing antitumor effects and systemic toxicities of cancer drug targets.
Li X; Huang CH; Sánchez-Rivera FJ; Kennedy MC; Tschaharganeh DF; Morris JP; Montinaro A; O'Rourke KP; Banito A; Wilkinson JE; Chen CC; Ho YJ; Dow LE; Tian S; Luan W; de Stanchina E; Zhang T; Gray NS; Walczak H; Lowe SW
Proc Natl Acad Sci U S A; 2022 Apr; 119(17):e2110557119. PubMed ID: 35442775
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Survivin Homodimerization Decreases Neuroblastoma Cell Growth.
Dorneburg C; Galiger C; Stadler GL; Westhoff MA; Rasche V; Barth TFE; Debatin KM; Beltinger C
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136322
[TBL] [Abstract][Full Text] [Related]
16. Dinaciclib, a Bimodal Agent Effective against Endometrial Cancer.
Howard D; James D; Murphy K; Garcia-Parra J; Pan-Castillo B; Rex S; Moul A; Jones E; Bilbao-Asensio M; Michue-Seijas S; Lutchman-Singh K; Margarit L; Francis LW; Rees P; Gonzalez D; Conlan RS
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33800911
[TBL] [Abstract][Full Text] [Related]
17. Generation of Orthotopic and Subcutaneous Patient-Derived Xenograft Models from Diverse Clinical Tissue Samples of Pediatric Extracranial Solid Tumors.
Hanssen KM; Fletcher JI; Kamili A
Methods Mol Biol; 2024; 2806():55-74. PubMed ID: 38676796
[TBL] [Abstract][Full Text] [Related]
18. Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance.
Chen P; Lee NV; Hu W; Xu M; Ferre RA; Lam H; Bergqvist S; Solowiej J; Diehl W; He YA; Yu X; Nagata A; VanArsdale T; Murray BW
Mol Cancer Ther; 2016 Oct; 15(10):2273-2281. PubMed ID: 27496135
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.
Rajput S; Khera N; Guo Z; Hoog J; Li S; Ma CX
Oncotarget; 2016 Aug; 7(35):56864-56875. PubMed ID: 27486754
[TBL] [Abstract][Full Text] [Related]
20. Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.
Danilov AV; Hu S; Orr B; Godek K; Mustachio LM; Sekula D; Liu X; Kawakami M; Johnson FM; Compton DA; Freemantle SJ; Dmitrovsky E
Mol Cancer Ther; 2016 Nov; 15(11):2758-2766. PubMed ID: 27550941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
